Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing incidence of ocular inflammation and related complications
3.2.1.2 Technological advancements
3.2.1.3 Rising expenditure on the R&D of novel treatments
3.2.1.4 Increase in awareness of eye disorders
3.2.2 Industry pitfalls & challenges
3.2.2.1 Complications and adverse drug events related to medications
3.2.2.2 Loss of patent protection for popular drugs
3.3 Growth potential analysis
3.4 Porter's analysis
3.4.1 Supplier power
3.4.2 Buyer power
3.4.3 Threat of new entrants
3.4.4 Threat of substitutes
3.4.5 Industry rivalry
3.5 PESTEL analysis
3.6 Reimburesemnt scenario
3.7 Regulatory landscape
3.8 Technological landscape
3.9 Future market trends
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Treatment Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Corticosteroids
5.3 Antibiotics
5.4 Analgesics
5.5 Antivirals
5.6 Antifungals
5.7 Other treatment types
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Topical
6.3 Oral
6.4 Injectables
Chapter 7 Market Estimates and Forecast, By Indication, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Uveitis
7.3 Conjunctivitis
7.4 Keratitis
7.5 Scleritis
7.6 Retinitis
7.7 Other indications
Chapter 8 Market Estimates and Forecast, By Cause, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 Infectious causes
8.3 Trauma and injury
8.4 Autoimmune diseases
8.5 Other causes
Chapter 9 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 AbbVie Inc.
10.2 Alimera Sciences
10.3 Bausch Health Companies Inc.
10.4 EyePoint Pharmaceuticals, Inc.
10.5 Novartis AG
10.6 Ocular Therapeutix, Inc.
10.7 Pfizer Inc.
10.8 Santen Pharmaceutical Co., Ltd.
